Cencora, Inc. $COR Shares Sold by Drucker Wealth 3.0 LLC

Key Points

• Drucker Wealth 3.0 LLC reduced its holdings in Cencora, Inc. by 34.5%, owning 2,484 shares worth $746,000 after the sale.
• Cencora reported earnings per share of $4.00 for the last quarter, exceeding analysts' expectations of $3.79, with revenue also surpassing estimates at $80.66 billion.
• The company's recent dividend was $0.55 per share, indicating a dividend yield of 0.7%, with a payout ratio of 22.63%.

Drucker Wealth 3.0 LLC cut its holdings in shares of Cencora, Inc. (NYSE:COR - Free Report) by 34.5% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,484 shares of the company's stock after selling 1,307 shares during the quarter. Drucker Wealth 3.0 LLC's holdings in Cencora were worth $746,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Cornerstone Planning Group LLC boosted its stake in Cencora by 106.7% during the first quarter. Cornerstone Planning Group LLC now owns 93 shares of the company's stock worth $26,000 after buying an additional 48 shares during the last quarter. Hoey Investments Inc. acquired a new position in Cencora in the 1st quarter valued at about $28,000. Costello Asset Management INC acquired a new position in Cencora in the 1st quarter valued at about $28,000. University of Texas Texas AM Investment Management Co. acquired a new position in Cencora in the 1st quarter valued at about $39,000. Finally, Golden State Wealth Management LLC lifted its holdings in Cencora by 157.6% in the first quarter. Golden State Wealth Management LLC now owns 170 shares of the company's stock valued at $47,000 after acquiring an additional 104 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors and hedge funds.

Cencora Price Performance

Cencora stock opened at $318.01 on Friday. The firm has a market cap of $61.66 billion, a PE ratio of 32.72, a price-to-earnings-growth ratio of 1.47 and a beta of 0.63. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. Cencora, Inc. has a 52-week low of $221.95 and a 52-week high of $319.68. The company's 50 day moving average is $296.99 and its two-hundred day moving average is $291.60.

Cencora (NYSE:COR - Get Free Report) last announced its quarterly earnings data on Wednesday, August 6th. The company reported $4.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.79 by $0.21. The business had revenue of $80.66 billion for the quarter, compared to analysts' expectations of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The company's revenue for the quarter was up 8.7% compared to the same quarter last year. During the same period last year, the firm earned $3.34 earnings per share. On average, research analysts expect that Cencora, Inc. will post 15.37 EPS for the current fiscal year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were issued a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Friday, August 15th. Cencora's dividend payout ratio (DPR) is presently 22.63%.

Insiders Place Their Bets

In other news, CEO Robert P. Mauch sold 5,097 shares of the firm's stock in a transaction on Thursday, September 18th. The shares were sold at an average price of $290.00, for a total value of $1,478,130.00. Following the sale, the chief executive officer directly owned 39,274 shares in the company, valued at approximately $11,389,460. This trade represents a 11.49% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Steven H. Collis sold 31,350 shares of the firm's stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the sale, the chairman owned 305,913 shares in the company, valued at approximately $88,671,942.18. This represents a 9.30% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 55,993 shares of company stock worth $16,292,923 over the last 90 days. Company insiders own 10.80% of the company's stock.

Analyst Upgrades and Downgrades

A number of research analysts recently commented on the company. Morgan Stanley set a $330.00 price objective on Cencora and gave the company an "equal weight" rating in a report on Wednesday, July 16th. Wells Fargo & Company upped their price target on Cencora from $337.00 to $354.00 and gave the company an "overweight" rating in a research note on Wednesday, August 13th. Wall Street Zen lowered Cencora from a "buy" rating to a "hold" rating in a research note on Saturday. Evercore ISI set a $340.00 target price on shares of Cencora in a research report on Wednesday. Finally, Jefferies Financial Group upped their price objective on shares of Cencora from $275.00 to $300.00 and gave the stock a "hold" rating in a report on Monday, June 30th. Nine research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat, Cencora currently has an average rating of "Moderate Buy" and an average price target of $320.00.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.